$20.960
-0.574 (-2.74%)收盤時
HQL 獲利能力與利潤率
Evaluating the bottom line, Abrdn Life Sciences Investors maintains a gross margin of 99.06%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 94.87%, while the net margin is 94.87%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively HQL converts its operational activities into shareholder value.
Financials
No data
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。